Endometrial Cancer GOG 229L

March 13, 2013

Location: The Hospital of Central Connecticut

A Phase II Trial of AMG 386 (IND#111071), A Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium.

Connect With Us

Subscribe to Our Newsletters

Get the latest healthcare news directly in your inbox.

Hartford HealthCare Offices

One State Street, Suite 19, Hartford, CT 06103 • Contact Us

Donations to Hartford HealthCare are managed by the Hartford Hospital Department of Philanthropy, a Connecticut tax-exempt organization under section 501(c)(3) of the IRS code (E.I.N. 06-0646668). For more information, click here.